Belldegrun Arie 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-13 7:09 pm Purchase | 2025-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 12,668,344 5.600% | 62,450 (+0.50%) | Filing |
| 2025-08-12 4:57 pm Purchase | 2025-06-30 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 12,605,894 5.700% | 62,450 (+0.50%) | Filing |
| 2025-05-09 5:30 pm Purchase | 2025-03-31 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 12,543,444 5.700% | 149,877 (+1.21%) | Filing |
| 2025-02-13 4:31 pm Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 12,393,567 5.800% | 2,497,664 (+25.24%) | Filing |
| 2024-02-14 4:36 pm Purchase | 2023-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 9,895,903 5.800% | 1,037,042 (+11.71%) | Filing |
| 2023-02-13 4:31 pm Purchase | 2022-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 8,858,861 6.100% | 1,655,613 (+22.98%) | Filing |
| 2022-02-14 3:36 pm Purchase | 2021-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 7,203,248 5.000% | 708,755 (+10.91%) | Filing |
| 2021-02-12 2:32 pm Sale | 2020-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Belldegrun Arie | 6,494,493 4.600% | -859,507 (-11.69%) | Filing |